Aburose
Nov 20, 9:56 PM
$NXTC NXTC has entered a new phase following the announcement of a definitive merger agreement with Avere Therapeutics—a deal that includes
$320 million in funding to develop a once-weekly oral treatment targeting an inflammation-related pathway.
0 replies